Niaspan monotherapy and combination of Niaspan with BMSC treatment of stroke substantially decrease Angiogenin, MMP9 and ED1 expression compared with BMSC monotherapy which may contribute to the attenuated BBB leakage and cerebral arteriosclerosis-like changes in the ischemic brain in T1DM rats after stroke. The gene discussed is MMP9; the disease is type 1 diabetes mellitus.